|
Volumn 19, Issue 16, 2011, Pages 4953-4970
|
Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554
|
Author keywords
Anti diabetic effects; Dipeptidyl peptidase IV (DPP 4); Isoquinolone
|
Indexed keywords
2 [[3 (AMINOMETHYL) 2 (2 METHYLPROPYL) 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLIN 6 YL]OXY]ACETAMIDE;
2 BUTYL 6 CHLORO 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
3 [3 (AMINOMETHYL) 2 (2 METHYLPROPYL) 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLIN 6 YL]PROP 2 ENAMIDE;
3 AMINOMETHYL 1,2 DIHYDRO 4 PHENYL 1 ISOQUINOLONE DERIVATIVE;
4 CHLORO 2 (PHENYLCARBONYL)BENZOIC ACID;
4 FLUORO 2 (PHENYLCARBONYL)BENZOIC ACID;
6 BROMO 1 OXO 4 PHENYL 1H ISOCHROMENE 3 CARBOXYLIC ACID;
6 BROMO 2 (2 METHYLPROPYL) 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
6 CHLORO 1 OXO 2 PENTYL 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
6 CHLORO 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
6 CHLORO 1 OXO 4 PHENYL 1H ISOCHROMENE 3 CARBOXYLIC ACID;
6 CHLORO 2 (2 METHYLPROPYL) 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
6 CHLORO 2 (2,2 DIMETHYLPROPYL) 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
6 CHLORO 2 ETHYL 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
6 CHLORO 2 METHYL 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
6 FLUORO 1 OXO 4 PHENYL 1H ISOCHROMENE 3 CARBOXYLIC ACID;
6 FLUORO 2 (2 METHYLPROPYL) 1 OXO 4 PHENYL 1,2 DIHYDROISOQUINOLINE 3 CARBOXYLIC ACID;
CYTOSOL AMINOPEPTIDASE;
DIPEPTIDYL PEPTIDASE;
DIPEPTIDYL PEPTIDASE 2;
DIPEPTIDYL PEPTIDASE I;
DIPEPTIDYL PEPTIDASE IV;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
GLUCOSE;
INSULIN;
LYSINE;
PHENYL GROUP;
PROLINE IMINOPEPTIDASE;
PROLYL ENDOPEPTIDASE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ALKOXYCARBONYLATION;
ALKYLATION;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ARTICLE;
BENZYLATION;
BINDING KINETICS;
CHEMICAL MODIFICATION;
CHLORINATION;
CONTROLLED STUDY;
CYCLIZATION;
DISEASE MODEL;
DRUG BINDING SITE;
DRUG DOSE COMPARISON;
DRUG EFFICACY;
DRUG POTENCY;
DRUG SELECTIVITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
ENZYME INHIBITION;
FEMALE;
GLUCOSE BLOOD LEVEL;
HUMAN;
HYDROGEN BOND;
HYDROLYSIS;
HYDROPHILICITY;
IC 50;
INSULIN BLOOD LEVEL;
METHANESULFONYLATION;
METHOXYCARBONYLATION;
METHYLATION;
MOLECULAR INTERACTION;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
ORAL GLUCOSE TOLERANCE TEST;
RAT;
RING OPENING;
SAPONIFICATION;
STRUCTURE ACTIVITY RELATION;
X RAY CRYSTALLOGRAPHY;
ADMINISTRATION, ORAL;
ANIMALS;
BLOOD GLUCOSE;
CACO-2 CELLS;
DIABETES MELLITUS, TYPE 2;
DIPEPTIDYL PEPTIDASE 4;
DIPEPTIDYL-PEPTIDASE IV INHIBITORS;
DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES;
DRUG DESIGN;
FEMALE;
GLUCOSE TOLERANCE TEST;
HUMANS;
HYPOGLYCEMIC AGENTS;
ISOQUINOLINES;
MOLECULAR TARGETED THERAPY;
PEPTIDES;
QUINOLONES;
RATS;
RATS, WISTAR;
STRUCTURE-ACTIVITY RELATIONSHIP;
RATTUS;
|
EID: 79961165720
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2011.06.059 Document Type: Article |
Times cited : (44)
|
References (33)
|